Sydney Jennings

Articles

Semaglutide May Reduce Alzheimer’s Risk in Adults with T2D: Daily Dose

November 05, 2024

Your daily dose of the clinical news you may have missed.

ObesityWeek 2024: Viking Therapeutics Presents New Positive Data from VK2735 Obesity Program

November 04, 2024

Results from the VENTURE phase 2 trial and a phase I oral formulation study found that VK2735, a dual GLP-1 and GIP receptor agonist, demonstrated promise in treating obesity.

Metabolic Bariatric Surgery Takes a Backseat as GLP-1RA Use Soars, According to New Research

November 04, 2024

Clinicians should continue to monitor trade-offs between pharmacologic and surgical management of obesity, researchers said.

FDA Approves New Treatment for Uncomplicated UTIs: Daily Dose

November 04, 2024

Your daily dose of the clinical news you may have missed.

Oral Semaglutide Linked to Lower Risk of MACE: Daily Dose

November 01, 2024

Your daily dose of the clinical news you may have missed.

Worst States for Health Care in the US: 2024

October 31, 2024

Get a quick look at the US worst states for health care ranked using a composite score that included measures of cost, access, and outcomes.

GLP-1RAs Reduce the Risk of Early-Onset Colorectal Cancer in Adults with T2D

October 31, 2024

ACG 2024: New study results indicate GLP-1 RAs have a potentially protective role to play in combating EO-CRC, the incidence of which is notably rising worldwide.

Social, Racial Disparities in Flu, COVID-19, RSV Vaccine Uptake: Daily Dose

October 31, 2024

Your daily dose of the clinical news you may have missed.

Modified Donanemab Dosing Reduces ARIA-E in Adults with Early Symptomatic Alzheimer Disease

October 30, 2024

New phase 3b data suggest that a modified titration of donanemab reduces the risk of brain swelling and fluid accumulation at 24 weeks.

Pneumococcal 21-Valent Conjugate Vaccine in At-Risk Adults: Daily Dose

October 30, 2024

Your daily dose of the clinical news you may have missed.